GlassScriptPhysician profile
Lance William Neveling
NPI 1255369369
$10,830.56
in general payments reported to CMS, 2019-2025
55 companies · $1,916 in 2025
The $1,916 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,068 · 2020: $783 · 2021: $965 · 2022: $1,298 · 2023: $2,248 · 2024: $1,552 · 2025: $1,916.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,697 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,696.94 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,419.31 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,176.71 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $927.22 | 2021-2025 | |
| Pfizer INC. | $865.97 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $781.70 | 2019-2024 | Xarelto |
| Daiichi Sankyo INC. | $667.51 | 2019-2024 | Injectafer |
| Merck Sharp & Dohme LLC | $517.65 | 2019-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Lilly USA, LLC | $437.37 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $413.85 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $347.45 | 2019-2025 | Xifaxan |
| Abbott Laboratories | $242.61 | 2022-2025 | Freestyle Libre 3 |
| Amgen INC. | $210.72 | 2019-2025 | Repatha, Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $205.97 | 2019-2023 | Stiolto Respimat, Spiriva Respimat |
| Astellas Pharma US INC | $205.11 | 2020-2025 | Veozah |
| Exact Sciences Corporation | $184.95 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lance Neveling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.